AZTA Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories, Inc. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of -52.36%. Azenta, Inc.'s return on equity of 1.7% beat Bio-Rad Laboratories, Inc.'s return on equity of 10.99%.

Azenta, Inc. has a consensus price target of $37.83, signalling upside risk potential of 70.87%. On the other hand Bio-Rad Laboratories, Inc. has an analysts' consensus of $321.25 which suggests that it could grow by 14.74%. Given that Azenta, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Azenta, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Azenta, Inc. has a beta of 1.466, which suggesting that the stock is 46.569% more volatile than S&P 500. In comparison Bio-Rad Laboratories, Inc. has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.649%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 1.65%. Bio-Rad Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Bio-Rad Laboratories, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $148.6M, which are smaller than Bio-Rad Laboratories, Inc. quarterly revenues of $693.2M. Azenta, Inc.'s net income of -$5.2M is lower than Bio-Rad Laboratories, Inc.'s net income of $720M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Bio-Rad Laboratories, Inc.'s PE ratio is 10.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 1.86x versus 2.97x for Bio-Rad Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of 2.99%. Azenta, Inc.'s return on equity of 1.7% beat Bruker Corp.'s return on equity of -0.39%.

Azenta, Inc. has a consensus price target of $37.83, signalling upside risk potential of 70.87%. On the other hand Bruker Corp. has an analysts' consensus of $47.86 which suggests that it could grow by 30.19%. Given that Azenta, Inc. has higher upside potential than Bruker Corp., analysts believe Azenta, Inc. is more attractive than Bruker Corp..

Azenta, Inc. has a beta of 1.466, which suggesting that the stock is 46.569% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.201, suggesting its more volatile than the S&P 500 by 20.087%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 1.65%. Bruker Corp. offers a yield of 0.53% to investors and pays a quarterly dividend of $0.05 per share. Azenta, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $148.6M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Azenta, Inc.'s net income of -$5.2M is lower than Bruker Corp.'s net income of $29.2M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 1.86x versus 1.66x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of -12%. Azenta, Inc.'s return on equity of 1.7% beat Harvard Bioscience, Inc.'s return on equity of -232.93%.

Azenta, Inc. has a consensus price target of $37.83, signalling upside risk potential of 70.87%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 15.39%. Given that Azenta, Inc. has higher upside potential than Harvard Bioscience, Inc., analysts believe Azenta, Inc. is more attractive than Harvard Bioscience, Inc..

Azenta, Inc. has a beta of 1.466, which suggesting that the stock is 46.569% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.498, suggesting its more volatile than the S&P 500 by 49.848%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 1.65%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $148.6M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $23.7M. Azenta, Inc.'s net income of -$5.2M is lower than Harvard Bioscience, Inc.'s net income of -$2.8M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 1.86x versus 0.88x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of 12.41%. Azenta, Inc.'s return on equity of 1.7% beat Revvity, Inc.'s return on equity of 3.2%.

Azenta, Inc. has a consensus price target of $37.83, signalling upside risk potential of 70.87%. On the other hand Revvity, Inc. has an analysts' consensus of $118.93 which suggests that it could grow by 33.72%. Given that Azenta, Inc. has higher upside potential than Revvity, Inc., analysts believe Azenta, Inc. is more attractive than Revvity, Inc..

Azenta, Inc. has a beta of 1.466, which suggesting that the stock is 46.569% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.128, suggesting its more volatile than the S&P 500 by 12.772%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 1.65%. Revvity, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.07 per share. Azenta, Inc. pays -- of its earnings as a dividend. Revvity, Inc. pays out 13.49% of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $148.6M, which are smaller than Revvity, Inc. quarterly revenues of $772.1M. Azenta, Inc.'s net income of -$5.2M is lower than Revvity, Inc.'s net income of $95.8M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Revvity, Inc.'s PE ratio is 43.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 1.86x versus 3.67x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.